Infinity Pharmaceuticals (NASDAQ: INFI)
Infinity Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Infinity Pharmaceuticals Company Info
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.
News & Analysis
Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today
An analyst initiated coverage of the biotech stock with a unambiguous buy recommendation.
Why Infinity Pharmaceuticals Is Skyrocketing Today
The company reported results from a clinical study.
What Investors Missed in the Stock Market Last Week
Investors were cautious towards the end of the trading week as the UK's vote to leave the EU looms.
Why Infinity Pharmaceuticals Inc. Is Being Obliterated Today
Disappointing results from a clinical trial cause traders to head for the exits.
Infinity Pharmaceuticals' Stock Dipped 15% in July: Time to Buy?
Infinity Pharmaceuticals' stock continued its recent nosedive in July. Is it now a compelling buy?
Why Infinity Pharmaceuticals Inc. Stock Skyrocketed
Infinity Pharmaceuticals stock is today's top gainer after forging a collaborative licensing deal for its lead experimental drug, IPI-145.
Why InterMune, Zulily, and Infinity Pharmaceuticals Are Today's 3 Best Stocks
Economic data pushes the S&P 500 marginally lower as InterMune, Zulily, and Infinity Pharmaceuticals all exploded higher.
Why Infinity Pharmaceuticals Inc. Shares Jumped
Shares of Infinity Pharmaceuticals jump by double-digits after reporting its fourth-quarter earnings results. Find out why investors would be wise to overlook the headline number and focus on this figure instead.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.